TSHA

With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessions, a combination of consumer reticence and stretched valuations means that many go-to investments may not see much near-term growth.

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.

Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027.

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity